BioDelivery Sciences International, Inc. (BDSI)
| Market Cap | 442.19M |
| Revenue (ttm) | 145.94M |
| Net Income (ttm) | 14.82M |
| Shares Out | 101.03M |
| EPS (ttm) | 0.15 |
| PE Ratio | 28.95 |
| Forward PE | 10.09 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $4.43 |
| Previous Close | $4.23 |
| Change ($) | 0.21 |
| Change (%) | 4.85% |
| Day's Open | 4.22 |
| Day's Range | 4.18 - 4.47 |
| Day's Volume | 1,031,429 |
| 52-Week Range | 2.85 - 5.45 |
Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory OutcomesComparing BELBUCA® to Oxycodone on January 16 from 1:10pm – 2:10pm CT
These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?
RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...
Let's see if BioDelivery Sciences International (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.
RALEIGH, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...
BioDelivery Sciences International, Inc. (BDSI) CEO Jeff Bailey on Q3 2020 Results - Earnings Call Transcript
Total Company Net Revenue Increased 30% versus Prior Year Reaching a Record $39.4 Million
RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...
RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...
RALEIGH, N.C., Oct. 23, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...
Investors who target growth may want to consider investing in the following small-cap stocks as they represent companies whose trailing 12-month pro forma earnings per share advanced significa...
New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) New Scientific Information Further Highlights Differentiated Clinical Prof...
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?
My Pound The Table Moment For BioDelivery Sciences
RALEIGH, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living wit...
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues.
BioDelivery Sciences International, Inc. (BDSI) Management on Q2 2020 Results - Earnings Call Transcript
BioDelivery (BDSI) delivered earnings and revenue surprises of -75.00% and 0.87%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences: Fundamentals Continue Divergence From Share Price
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?
RALEIGH, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with s...
BioDelivery Sciences: Undervalued $5 Biopharma Still Growing Despite COVID-19
BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues.
BioDelivery Sciences International, Inc. (BDSI) CEO Herm Cukier on Q1 2020 Results - Earnings Call Transcript
BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 15.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioDelivery Sciences Strong As Ever But At Half The Price
BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.
BioDelivery Sciences International, Inc. (BDSI) CEO Herm Cukier on Q4 2019 Results - Earnings Call Transcript
BioDelivery (BDSI) delivered earnings and revenue surprises of 700.00% and 4.98%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Mr. Bailey Further Strengthens Company Leadership Bringing more than 30 Years of Significant Industry Experience including Commercial Operations and Board Management Mr. Bailey Further Strengt...
BELBUCA® Effect on Respiratory Drive was Comparable to Placebo in Clinical Trial at all Tested Doses
Here are five reasons which make BioDelivery (BDSI)) a good investment option in 2020.
When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. Here are seven that stand out according to the Street.
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
RALEIGH, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with...
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
RALEIGH, N.C., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to pat...
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Selecting breakout stocks continues to be one of the most popular methods utilized by active investors.
About BDSI
BioDelivery Sciences International, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to trea... [Read more...]
| Industry Biotechnology | Founded 1997 |
| CEO Jeffrey Bailey | Employees 178 |
| Stock Exchange NASDAQ | Ticker Symbol BDSI |
Financial Performance
In 2019, BDSI's revenue was $111.39 million, an increase of 100.20% compared to the previous year's $55.64 million. Losses were -$15.31 million, -54.81% less than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for BDSI stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 80.59% from the latest price.